Cameron Haery, MD Department of Cardiovascular Medicine, The Cleveland Clinic Foundation
Ravish Sachar, MD Department of Cardiovascular Medicine, The Cleveland Clinic Foundation
Stephen G. Ellis, MD Director, Sones Catheterization Laboratories, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation
Address: Stephen G. Ellis, MD, Director, Sones Catheterization Laboratories, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail elliss@ccf.org
Dr. Ellis has indicated that he has received grant or research support from the Cordis and Medtronic corporations and serves as a consultant for the Cordis, Boston Scientific, and Guidant corporations.
This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.
ABSTRACTIn multiple clinical trials, patients who received drug-eluting stents instead of plain stents during percutaneous coronary interventions had rates of restenosis that were lower by roughly one half to three fourths, depending on how restenosis was defined and on the population studied. These stents will likely be used more and more as their indications evolve.
